LX
Lexicon Pharmaceuticals, Inc.
LXRX · NASDAQ
$2.24 -0.44% (-$0.01)
1M -6.67%
Market Cap $995.0M
P/E Ratio -
Div. Yield -
ROE 40.40%
Bulios Fair Price
$2.66
18.7% upside
Current Price
$2.24
Undervalued Fair Value Overvalued
According to Bulios Fair Price, LXRX is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
15 /100
Expensive P/S 23.99x
P/B 5.70x
P/E N/A
Growth
80 /100
Growing Rev. growth 610.25%
Book val. growth 2.81%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 98.85%
Net margin 147.38%
FCF margin 192.24%
Quality
2 /100
Poor ROIC 23.00%
ROE 40.40%
Asset turnover 0.17x
Debt
68 /100
Low Debt/Equity 0.34x
Current ratio 13.37x
Int. coverage -6.29x
Stability
32 /100
Unstable Beta 1.03x
Rev. volatility 1,245.19%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LXRX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael S. Exton
Employees
81
Headquarters
The Woodlands
Upcoming events
05 NOV
Earnings
Upcoming earnings report